Abstract
DeepCandida infections are increasing in incidence, especially in non-neutropenic, intensive care patients including neonates. The attributable mortality of candidaemia andcandida peritonitis is 37–38% with a 57% overall mortality. The BSAC set up a working party to develop recommendations for management in the absence of controlled trials. These recommendations focus on the role of the microbiology laboratory, management strategies, the respective roles of amphotericin B, flucytosine and fluconazole and long-term maintenance therapy. The indications for initiation of therapy are given special consideration.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Komshian SV, Uwaydah AK, Sobel JD, Crane LR (1989) Fungemia caused byCandida species andTorulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 11:379–390
Wenzel RP, Pfaller MA (1991)Candida species: emerging hospital bllodstream pathogens. Infect Control Hosp Epidemiol 12:523–524
Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC (1992) Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 15:414–421
Denning DW (1991) Epidemiology and pathogenesis of systemic fungal infection in the immunocompromised host. J Antimicrob Chemother 28 [Suppl B]:1–16
Edwards JE (1991) Invasivecandida infections. Evolution of a fungal pathogen. N Engl J Med 324:1059–1062
Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP (1988) Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 148:2642–2645
Johnson D, Thompson T, Green T, Ferrieri P (1984) Systemic candidiasis in very low birth weight infants (<1500 g). Pediatrics 73:138–143
Baley J, Kleigman R, Fanaroff A (1984) Disseminated fungal infections in very low birth weight infants: Clinical manifestations and epidemiology. Pediatrics 73:144–152
Sanchez P, Siegel J, Fishbein J (1991)Candida endocarditis: successful medical management in three preterm infants and review of the literature. Pediatr Infect Dis J 10:239–243
British Society for Antimicrobial Chemotherapy Working Party (1987) Diagnosis and management of peritonitis in continuous ambulatory peritoneal dialysis. Lancet I:845–849
Leen CLS, Brettle RP (1991) Fungal infections in drug abusers. J Antimicrobial Chemother 28 [Suppl A]:83–96
British Society for Antimicrobial Chemotherapy Working Party on Fungal Infection (1992) Treatment of fungal infections in AIDS. Lancet 340:648–651
Dupont B (1991) Clinical manifestations and management of candidosis in the compromised patient. In: Warnock DW, Richardson MD (eds) Fungal infection in the compromised patient. Wiley, Chichester, pp 55–83
EPIC Study Group (1992) The EPIC study — preliminary results. HOST 9:12–13
Calandra T, Bille J, Schneider R, Mosimann F, Francioli P (1989) Clinical significance ofCandida isolated from peritoneum in surgical patients. Lancet II:1437–1440
Bayer AS, Blumenkrantz MJ, Montgomerie JZ, Galpin JE, Coburn JW, Guze LB (1976)Candida peritonitis: report of 22 cases and review of the English literature. Am J Med 61:832–840
British Society for Antimicrobial Chemotherapy Working Party on Fungal Infection (1991) Laboratory monitoring of antifungal chemotherapy. Lancet 357:1577–1580
Powderly WG, Kobayashi GS, Herzig GP, Medoff G (1988) Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med 84:826–832
O'Day DM, Ray WA, Robinson RD, Head WS, Williams TE (1991) Differences in response in vivo to amphotericin B amongCandida albicans strains. Invest Ophthalmol Vis Sci 32:1569–1572
Warnock DW, Burke J, Cope NJ, Johnson EM, von Fraunhofer NA, Williams EW (1988) Fluconazole resistance inCandida glabrata. Lancet II:1310
Vanden Bossche H, Marichal P, Odds FC, Le Jeune L, Coene M-C (1992) Characterization of an azole resistantCandida glabrata isolate. Antimicrob Agents Chemother 36:2602–2610
Seidenfeld SM, Cooper BH, Smith JW, Luby JP, Mackowiak PA (1983) Amphotericin B tolerance: a characteristic ofCandida parapsilosis not shared by otherCandida species. J Infect Dis 147:116–119
Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R (1991) Increase inCandida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 325:1274–1277
Pappagianis D, Collins MS, Hector R, Remington J (1979) Development of resistance to amphotericin B inCandida lusitaniae infecting in human. Antimicrob Agents Chemother 16:123–126
Blinkhorn RJ, Adelstein D, Spagnuolo PJ (1989) Emergence of a new opportunistic pathogen,Candida lusitaniae. J Clin Microbiol 27:236–240
British Society for Antimicrobial Chemotherapy Working Party on Fungal Infection (1993) Antifungal prophylaxis in leukaemia and transplantation. J Antimicrob Chemother 32:5–21
Rubin RH (1991) Preemptive therapy in immuncompromised hosts. N Engl J Med 324:1057–1058
Schmidt GM, Horak DA, Niland JC et al (1991) A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogenic bone marrow transplants. N Engl J Med 324:1005–1011
Brajtburg J, Powderly WG, Kobayashi GS, Medoff G (1990) Amphotericin B: delivery systems. Antimicrob Agents Chemother 34:381–384
Clark JM, Whitney RR, Olsen SJ, George RJ, Swerdel MR, Kunselman L, Bonner DP (1991) Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 35:615–621
Clemons KV, Stevens DA (1992) Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis. J Antimicrob Chemother 30:353–363
Van't Wout JW, Mattie H, Van Furth R (1988) A prospective study of the efficacy of fluconazole (UK-49,858) against deep-seated fungal infections. J Antimicrob Chemother 21:665–672
Ikemoto H (1989) A clinical study of fluconazole in the treatment of deep mycoses. Diagn Microbiol Infect Dis 12:S329-S247
Nolla-Salas J, León C, Torres-Rodríguez JM, Martín E, Sitges-Serra A (1992) Treatment of candidemia in critically ill surgical patients with intravenous fluconazole. Clin Infect Dis 14:952–954
Rex JH, Bennett JE, Sugar AM et al (1993) Fluconazole (FLU) vs. Amphotericin B (AMB) for treatment of candidemia: results of a randomized, multicenter trial. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, October 17–20, 1993. American Society for Microbiology: Abstract 805
Graninger W, Presteril E, Schneeweiss B, Teleky B, Georgopoulos A (1992) Treatment ofCandida albicans fungaemia with fluconazole. J Infect 26:133–146
Kujath P, Lerch K (1989) New antimicrobial agents under clinical investigation. Secondary mycosis in surgery: treatment with fluconazole. Infection 13:111–117
Eppes SC, Troutman JL, Gutman LT (1989) Outcome of treatment of candidemia in childen whose central catheters were removed or retained. Pediatr Infect Dis J 8:99–104
Dato VM, Dajani AS (1990) Candidemia in children with central venous catheters: role of catheter removal and amphotericin B therapy. Pediatr Infect Dis J 9:309–314
Sanford JP (1993) The enigma of candiduria: Evolution of bladder irrigation with amphotericin B for management — from anecdote to dogma and a lesson from Machiavelli. Clin Infect Dis 16:145–147
Walsh TJ, Hutchins GM, Bulkley BH, Mendelsohn G (1980) Fungal infections of the heart: analysis of 51 autopsy cases. Am J Cardiol 45:357–366
Rubinstein E, Noriega ER, Simberkoff MS, Holzman R, Rahal JJ (1975) Fungal endocarditis: analysis of 24 cases and review of the literature. Medicine 54:331–344
Weems JJ (1992)Candida parapsilosis: Epidemiology, pathogenicity, clinical manifestations and antimicrobial susceptibility. Clin Infect Dis 14:756–766
Rudd RM, Hill PR, Kopelman P, Parker DJ (1980) Fungal endocarditis after homograft valve replacement: difficulties in diagnosis and treatment. Thorax 35:686–689
Galgiani JN, Stevens DA (1977) Fungal endocarditis: need for guidelines in evaluating therapy. J Thorac Cardiovasc Surg 73:293–296
Walsh TJ, Bustamente CI, Vlahov D, Standiford HC (1986) Candidal suppurative peripheral thrombophlebitis: recognition, prevention, and management. Infect Control 7:16–22
Lipton SA, Hickey WF, Morris JH, Losclzo J (1984) Candidal infection in the central nervous system. Am J Med 76:101–108
Brooks RG (1989) Prospective study ofCandida endophthalmitis in hospitalized patients with candidemia. Arch Intern Med 149:2226–2228
Schmid S, Martenet AC, Oelz O (1991)Candida endophthalmitis: Clinical presentation, treatment and outcome in 23 patients. Infection 19:21–24
Author information
Authors and Affiliations
Consortia
Additional information
Participants: J. Cohen, Chairman, Royal Postgraduate Medical School, London; D. W. Denning, Rapporteur, North Manchester General and Hope Hospitals and University of Manchester; E. G. V. Evans, University of Leeds; R. J. Hay, United Medical and Dental Schools of Guy's and St. Thomas' Hospital, London; D. W. R. Mackenzie, London School of Hygiene and Tropical Medicine,; A.G. Prentice, Derriford Hospital, Plymouth; T.R.F. Rogers, Royal Postgraduate Medical School, London; D.C.E. Speller, University of Bristol, Bristol; D.W. Warnock, Public Health Laboratory, Bristol; R.E. Warren, Royal Shrewsbury Hospital, Shrewsbury
Rights and permissions
About this article
Cite this article
British Society for Antimicrobial Chemotherapy Working Party., Denning, D.W. Management of deepCandida infection in surgical and intensive care unit patients. Intensive Care Med 20, 522–528 (1994). https://doi.org/10.1007/BF01711909
Issue Date:
DOI: https://doi.org/10.1007/BF01711909